EIMindA Ltd.’s Brain Network Activity (BNA) Analysis System, which assesses brain function, has been approved by the U.S. Food and Drug Administration (FDA). The BNA uses non-invasive, multi-channel EEG technology in combination with advanced signal processing and analysis algorithms to measure patterns of brain networks that are triggered during different brain processes. The system gives both quantitative and qualitative insights into brain functionality.

The BNA is currently cleared for 14-24 year olds, with EIMindA researching to expand the age group. The BNA output will let healthcare providers compare a patient’s functional brain network activity to that of a healthy brain. The system gives a necessary objective layer of information when conducting tests for brain health. BNA gives access to brain health by using objective neurological measurements. These measurements differentiate a healthy brain from one that is otherwise affected. Thus far, EIMindA has a database of brain activity (both healthy and not) that includes over 7,000 BNA datasets.